… Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and … and imdevimab) against
SARS-CoV-2 was approved for … against SARS--CoV-2 and its rapidly emerging variants. …

… specificity and reliability, monoclonal antibodies (mAbs) … coronavirus 2 (SARS-CoV-2)
and Ab drugs for use as COVID-19 therapeutic agents. The detailed structure of the SARS-CoV-2 …

… Numerous mAbs have been developed against SARS-CoV 2 and have proven their … describe
the monoclonal antibodies currently authorized for the treatment of the coronavirus disease …

… Monoclonal antibodies (mAbs) targeting the spike protein of SARS-CoV-2 have been widely
used in the ongoing COVID-19 pandemic. In this paper, we review the properties of mAbs …

… Monoclonal antibodies (mAbs) offer a treatment option for … evolution of resistance to
mAbs by SARS-CoV-2, we reviewed … is being reported with new SARS-CoV-2 variants. The …

… neutralizing antibodies against variant strains of SARS-CoV-2 … activity of a panel of monoclonal
antibodies (mAbs), which … , Regeneron and Lilly, against SARS-CoV-2 variant viruses. …

… of newly emerging SARS-CoV-2 variants, we suggest the importance of rapid evaluation
of the efficiency of therapeutic monoclonal antibodies against novel SARS-CoV-2 variants. …

… acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Similar to all viruses, SARS-CoV-2
is … neutralizing monoclonal antibodies (mAbs) targeting the SARS-CoV-2 spike protein ( …

… immune reactivity of human monoclonal antibody made against SARS-CoV-2 spike protein
and nucleoprotein and rabbit polyclonal antibody made against SARS-CoV-2 envelope and …

… antibodies ineffective. Here, we completely map all of the mutations to the SARS-CoV-2 spike
receptor-binding domain (RBD) that escape binding by a leading monoclonal antibody, LY-…